85 Phase 3 LITESPARK-033 (NCT07227402) Study of Belzutifan Plus Zanzalintinib Versus Cabozantinib for Recurrent Clear Cell Renal Cell Carcinoma During or After Adjuvant Anti–PD-(L)1 Therapy - Toni K Choueiri; Thomas Powles; Martin H Voss; Marc-Oliver Grimm; Kelly N Fitzgerald; Brian Simmons; Jerry Cornell; Joseph E Burgents; Priyanka Chablani; Cristina Suarez (The Oncologist, 2026)